Status:
COMPLETED
Influence of Cardiac Implantable Electronic Devices on the Hemostatic System
Lead Sponsor:
Ryazan State Medical University
Conditions:
Thromboembolism
Cardiac Event
Eligibility:
All Genders
40+ years
Brief Summary
The hemostasis system is one of the many biological systems of the human body, designed to preserve the liquid state of blood and prevent its loss during vascular injuries. The ideal balance between i...
Detailed Description
250 patients of similar age, gender, and ethnicity will be divided into five groups: Group A1-3: 150 patients with indications for cardiac implantable electronic device (CIED) implantation; Group B: 5...
Eligibility Criteria
Inclusion
- for group A1-3: atrioventricular block/sick sinus syndrome/atrial fibrillation with impaired conduction as indications for cardiac implantable electronic device implantation;
- for group B: atrioventricular block/sick sinus syndrome/atrial fibrillation with impaired conduction and cardiac implantable electronic device implanted 6-12 years ago;
- for group C: atrioventricular block/sick sinus syndrome/atrial fibrillation with impaired conduction without indications for cardiac implantable electronic device implantation.
Exclusion
- active cancer or a remission period of less than 5 years;
- decompensated somatic pathology;
- pregnancy or breastfeeding in women.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04499612
Start Date
March 1 2020
End Date
November 1 2023
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ryazan State Medical University
Ryazan, Ryazan Oblast, Russia